Pharmaceuticals News

Cosmos Health has now repurchased a total of 4,355,000 shares for approximately $901,000.

Cosmos Health accelerates prescription medicine strategy with Libytec partnership to commercialize DIABIT-IS X in Greece.

這項全國計劃會採用 Alamar Biosciences 的 NULISAseq™ Neuro 220 多重檢測組合試劑盒，分析來自 10,000 名阿茲海默症及相關認知障礙症 (ADRD) 參與者約 21,000 份的血漿樣本。 研究所得的數據集將全面開放，經由 National Alzheimer’s Coordinating Center...

这项全国性研究计划将利用 Alamar Biosciences 的 NULISAseq™ Neuro 220 检测试剂盒，对 10,000 名阿尔茨海默病及相关痴呆症 (ADRD) 受试者提供的约 21,000 万份血浆样本开展图谱分析。 生成的数据集将对外开放，可通过 National Alzheimer’s Coordinating Center (美国国家阿尔茨海默病协调中心)...

First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation TrustZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical developmentZIMA-101...

Første pasient dosert med ZI-MA4-1 ved The Christie NHS Foundation Trust. ZI-MA4-1 er verdens første MAGE-A4-rettede TCR-NK-terapi som nå testes i pasienter for første gangMed ZIMA-101 testes...

Company announcement No. 32 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 28, 2026) Copenhagen, Denmark, July 13, 2026 – Zealand Pharma A/S ("the Company" or “Zealand...

LONDON, July 13, 2026 (GLOBE NEWSWIRE) -- Scottish brewer and the UK’s leading craft beer brand BrewDog, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), today announced that BrewDog...

Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care,...

COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory...